Learn More
OBJECTIVE To review the evidence for the use of bisphosphonates to reduce skeletal morbidity in cancer patients with bone metastases. DATA SOURCES Electronic databases, scanning reference lists, and consultation with experts and pharmaceutical companies. Foreign language papers were included. STUDY SELECTION Included trials were randomised controlled(More)
OBJECTIVES To identify evidence for the role of bisphosphonates in malignancy for the treatment of hypercalcaemia, prevention of skeletal morbidity and use in the adjuvant setting. To perform an economic review of current literature and model the cost effectiveness of bisphosphonates in the treatment of hypercalcaemia and prevention of skeletal morbidity.(More)
BACKGROUND Bisphosphonates are the treatment of choice for hypercalcaemia of malignancy (HCM) but there is no consensus regarding which drug or dose should be given. We designed a systematic review to investigate the efficacy of bisphosphonates in the treatment of HCM. METHODS We identified randomized controlled trials (RCTs) by searching electronic(More)
1 Department of Palliative Medicine, Royal Marsden Hospital, London, UK 2 Department of Palliative Care and Policy, King’s College, London, UK 3 Systematic Reviews Training Unit, Institute of Child Health, London, UK 4 Health Services Research Unit, London School of Hygiene and Tropical Medicine, London, UK 5 Department of Epidemiology and Population(More)
The numbers of patients with end-stage renal disease are growing, with a disproportionate increase among those who are elderly, dependent and with multiple co-morbidities. More of these patients are choosing to be managed conservatively, without dialysis. Palliative provision for these patients within UK renal services is limited, but the recent National(More)
  • 1